NASDAQ · NKTR
Nektar Therapeutics
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for NKTR: Nov 5, 2026
Nektar Therapeutics Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 10 analysts' forecasts, the consensus EPS forecast for the quarter is $-2.16. The reported EPS for the same quarter last year was $-1.85.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-2.16 | $-1.71 | $-3.07 | 10 |
| Dec 2026 | $-2.77 | $-2.14 | $-3.53 | 10 |
| Mar 2027 | $-2.91 | $-2.15 | $-4.30 | 6 |
| Jun 2027 | $-2.75 | $-1.19 | $-5.07 | 6 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · Fintel · BNK Invest · MarketBeat- Zacks · Oct 29, 9:00 AM EDTNektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 15, 11:31 AM EDTCan Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?NKTR advances rezpeg into phase III studies for atopic dermatitis, with additional autoimmune indications offering potential growth amid stiff competition.
- Fintel · Oct 12, 9:13 PM EDTLeerink Partners Initiates Coverage of Nektar Therapeutics at OutperformFintel reports that on October 12, 2026, Leerink Partners initiated coverage of Nektar Therapeutics (NASDAQCM:NKTR) (BMV:NKTR) with a Outperform recommendation. On the same day, UBS also initiated coverage of the company with a Neutral rating, representing the 2 same-day analyst
- Fintel · Oct 9, 8:04 PM EDTRaymond James Initiates Coverage of Nektar Therapeutics with Market PerformFintel reports that on October 9, 2026, Raymond James initiated coverage of Nektar Therapeutics (NASDAQCM:NKTR) (BMV:NKTR) with a Market Perform recommendation.On the same day, BTIG reiterated its Buy rating for the company. Prior to these actions, the stock closed at $40.80 on O
- BNK Invest · Oct 1, 3:26 PM EDTNoteworthy Thursday Option Activity: NKTR, MSGS, TRNSLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Nektar Therapeutics (Symbol: NKTR), where a total volume of 13,079 contracts has been traded thus far today, a contract volume which is representative of approxi
- MarketBeat · Oct 1, 12:02 PM EDTNektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial3 Bullish Biotech Stocks With Explosive Growth TrendsNektar Therapeutics (NASDAQ:NKTR) presented new clinical and biomarker findings for rezpegaldesleukin, or REZPEG, at the EADV 2026 Congress, highlighting six-month off-treatment results in severe to very severe alopecia areata
- RTTNews · Oct 1, 10:31 AM EDTNektar Reports Durable Rezpegaldesleukin Data In Alopecia Areata And Atopic Dermatitis(RTTNews) – On Thursday, Nektar Therapeutics (NKTR) reported new long-term data from the Phase 2b REZOLVE-AA and REZOLVE-AD studies of rezpegaldesleukin in alopecia areata and atopic dermatitis, respectively.
- RTTNews · Sep 30, 10:55 AM EDTNektar Advances Rezpegaldesleukin In Atopic Dermatitis With Early Biomarker Data(RTTNews) – Nektar Therapeutics (NKTR) reported new biomarker data from the Phase 2b REZOLVE-AD study showing that rezpegaldesleukin produced molecular changes across multiple immune pathways as early as Week 2 in patients with moderate-to-severe atopic dermatitis.
- The Motley Fool · Aug 20, 7:34 PM EDTNektar (NKTR) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 14, 11:02 AM EDTNektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in FocusNKTR's Q2 earnings beat estimates, but revenues fall short. Investor focus stays on rezpeg as late-stage studies advance in autoimmune diseases.
- Zacks · Aug 14, 10:36 AM EDTRetail Sales Weaken in JulyRetail Sales Weaken in July
- Zacks · Aug 14, 10:29 AM EDTU.S. Stock Futures Mixed, Heads for a Winning WeekU.S. Stock Futures Mixed, Heads for a Winning Week.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Nektar Therapeutics from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.